Table 2.
Characteristics of the randomized studies included in this systematic review.
| Num | Author/Study | With treatment (surgical), n (%) | Follow-up (mo) | Without treatment (control), n (%) | Follow-up (mo) | Gastric cancer stages, n (%) | ||
|---|---|---|---|---|---|---|---|---|
| Survival | Death | Survival | Death | |||||
| 1 | Aviles, et al (2006). Surgery and chemotherapy versus chemotherapy as treatment of high-grade MALT gastric lymphoma | 38 (77.55) | 11 (22.45) | 60 | 36 (75.00) | 12 (25.00) | 60 | I: 21 (21.6), II: 76 (78.4) |
| 2 | Aviles, et al (2004). The role of surgery in primary gastric lymphoma results of a controlled clinical trial | 211 (48.06) | 228 (54.94) | 120 | 144 (96.00) | 6 (4.00) | 120 | I: 404 (68.6); II: 185 (31.4) |
| 3 | Gallardo-Rincon, et al (2000). Neoadjuvant chemotherapy with P-ELF (cisplatin, etoposide, leucovorin, 5-fluorouracil) followed by radical resection in patients with initially unresectable gastric adenocarcinoma: a phase II study | 5 (50.00) | 5 (50.00) | 13 | 17 (36.18) | 30 (63.82) | 8 | III: 20 (33.3); IV: 40 (66.7) |